JPRN-jRCT2080223480
Unknown
Phase 2
Phase 2a exploratory, randomized, double-blind, parallel-group study of ONO-8577 compared to combination of solifenacin succinate/ mirabegron for overactive bladder
ConditionsOveractive bladder
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Overactive bladder
- Sponsor
- ONO PHARMACEUTICAL CO.,LTD.
- Enrollment
- 200
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Sexes: Both
- •2\. Ages: 20 years to 80 years
- •3\. Patient with symptoms of overactive bladder for \>\=6 months
Exclusion Criteria
- •1\. Patient with genuine stress incontinence, or with stress\-predominant mixed urinary incontinence
- •2\. Patient who has never experienced urge urinary incontinence during disease duration of overactive bladder
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A study to evaluate the effectiveness and safety of study drug (sepranolone) in women with menstrual migraineEUCTR2019-001081-15-FIAsarina Pharma ApS84
Active, not recruiting
Phase 1
A study to evaluate the effectiveness and safety of study drug (sepranolone) in women with menstrual migraineEUCTR2019-001081-15-SEAsarina Pharma ApS84
Active, not recruiting
Phase 1
An exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel design study to evaluate the safety, tolerability, and pharmacodynamics of AZD1722 in CKD patients with type 2 diabetes mellitus and albuminuriaChronic kidney disease (CKD) with type 2 diabetes mellitus and albuminuriaMedDRA version: 17.0Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857Therapeutic area: Not possible to specifyEUCTR2013-005345-36-DEArdelyx, Inc.140
Active, not recruiting
Phase 1
A Safety and Efficacy Study of GWP42003-P (Cannabidiol; CBD) in Children and Young Adults with Autism Spectrum Disorder.Autism Spectrum Disorder (ASD)MedDRA version: 21.1Level: PTClassification code 10063844Term: Autism spectrum disorderSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2020-002819-21-DEGW Research Ltd103
Active, not recruiting
Phase 1
A Safety and Efficacy Study of GWP42003-P (Cannabidiol; CBD) in Children and Young Adults with Autism Spectrum Disorder.Autism Spectrum Disorder (ASD)MedDRA version: 21.1Level: PTClassification code 10063844Term: Autism spectrum disorderSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2020-002819-21-ESGW Research Ltd160